Τίτλος:
Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and developmental pathways. Research on prediagnosis androgen concentrations and EOC risk has yielded inconclusive results, and analyses incorporating EOC subtypes are sparse. We conducted a pooled analysis of 7 nested case-control studies in the Ovarian Cancer Cohort Consortium to investigate the association between prediagnosis circulating androgens [testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS)], sex hormone binding globulin (SHBG), and EOC risk by tumor characteristics (i.e., histology, grade, and stage). The final study population included 1,331 EOC cases and 3,017 matched controls. Multivariable conditional logistic regression was used to assess risk associations in pooled individual data. Testosterone was positively associated with EOC risk (all subtypes combined, ORlog2 = 1.12; 95% confidence interval 1.02-1.24); other endogenous androgens and SHBG were not associated with overall risk. Higher concentrations of testosterone and androstenedione associated with an increased risk in endometrioid andmucinous tumors [e.g., testosterone, endometrioid tumors, ORlog2 = 1.40 (1.03-1.91)], but not serous or clear cell. An inverse association was observed between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60-0.96)]. Our analyses provide further evidence for a role of hormonerelated pathways in EOC risk, with differences in associations between androgens and histologic subtypes of EOC. © 2017 American Association for Cancer Research.
Συγγραφείς:
Ose, J.
Poole, E.M.
Schock, H.
Lehtinen, M.
Arslan, A.A.
Zeleniuch-Jacquotte, A.
Visvanathan, K.
Helzlsouer, K.
Buring, J.E.
Lee, I.-M.
Tjønneland, A.
Dossus, L.
Trichopoulou, A.
Masala, G.
Onland-Moret, N.C.
Weiderpass, E.
Duell, E.J.
Idahl, A.
Travis, R.C.
Rinaldi, S.
Merritt, M.A.
Trabert, B.
Wentzensen, N.
Tworoger, S.S.
Kaaks, R.
Fortner, R.T.
Περιοδικό:
Clinical Cancer Research
Εκδότης:
American Association for Cancer Research Inc.
Λέξεις-κλειδιά:
androgen; androstenedione; prasterone sulfate; sex hormone binding globulin; testosterone; androgen, androstenedione blood level; Article; cancer grading; cancer risk; cancer staging; case control study; concentration (parameters); disease association; endometrioid carcinoma; female; histology; hormone determination; human; neoplasm; ovary carcinoma; priority journal; protein blood level; risk assessment; testosterone blood level; classification; cohort analysis; metabolism; ovary tumor; pathology; risk factor, Androgens; Cohort Studies; Female; Humans; Ovarian Neoplasms; Risk Factors
DOI:
10.1158/0008-5472.CAN-16-3322
